A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Phase 2CompletedNCT01965613

Janssen Research & Development, LLC10 enrolled

Overview

The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.

XBiotech owned bermekimab and sponsored and completed study prior to Dec 30, 2019.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pyoderma Gangrenosum

Interventions

XilonixBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age: ≥18 2. History of pyoderma gangrenosum with or without other systemic disease. Exclusion Criteria: 1. Treatment with any biologicals (including intravenous immunoglobulin) or investigational agents within the last 4 weeks (or 5 half-lives, whichever is longer). 2. Treatment with corticosteroids or cyclosporine within the last 2 weeks.

Locations (1)

XBiotech Investigative Site

Tallahassee, Florida, United States

Outcomes

Primary Outcomes

Change in Physician's Wound Assessment & Patient's Global Assessment

Time frame: 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.